Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review
María López-Santillán, Elixabet López-López, Paula Álvarez‐González, Garazi Martínez, Javier Arzuaga‐Méndez, Irune Ruiz-Díaz, Isabel Guerra‐Merino, Ángela Gutiérrez-Camino, Idoia Martín‐Guerrero
Abstract
Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line therapy, which fails in 30-40 % of patients, who are either refractory or relapse after remission. With the aim of stratifying patients to improve treatment outcome, different clinical and genetic biomarkers have been studied. The present systematic review aimed to identify somatic mutations that could serve as prognosis biomarkers or as therapeutic target mutations in DLBCL. Regarding their role as prognostic markers, mutations in CD58 and TP53 seem the most promising predictors of poor outcome although the combination of different alterations and other prognostic factors could be a more powerful strategy. On the other hand, different approaches regarding targeted therapy have been proposed. Therefore, mutational analysis could help guide treatment choice in DLBCL yet further studies and clinical trials are needed.